Workflow
This
page
is
part
of
the
Continuous
Integration
Build
of
FHIR
Specification
(v4.0.1:
R4
-
Mixed
Normative
and
STU
)
in
it's
permanent
home
(it
will
always
(will
be
available
incorrect/inconsistent
at
this
URL).
The
current
version
which
supercedes
this
version
is
5.0.0
.
For
a
full
list
of
available
versions,
see
times).
See
the
Directory
of
published
versions
.
Page
versions:
R5
R4B
R4
R3
| Responsible Owner: Clinical Decision Support Work Group | Standards Status : Informative |
Compartments
:
|
Raw JSON ( canonical form + also see JSON Format Specification )
Chemotherapy Regimen
{
"resourceType": "PlanDefinition",
"id": "KDN5",
"text": {
"status": "additional",
"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n <table style=\"width: 100%;\">\n <tr>\n <td>\n <!-- link to NCCN image -->\n <div style=\"width: 200px; height: 100px; vertical-align: top;\">National Comprehensive Cancer Network</div>\n </td>\n <td>\n <h3>Chemotherapy Order Template</h3>\n <h1>Kidney Cancer</h1>\n <h2>Gemcitabine/CARBOplatin</h2>\n </td>\n <td style=\"text-align: right; vertical-align: top;\">KDN5</td>\n </tr>\n </table>\n <table style=\"width: 100%; border-top: 1px solid; border-bottom: 1px solid;\">\n <tr>\n <td style=\"width: 33%; border-right: 1px solid; vertical-align: top\">\n <h4>INDICATION:</h4>\n <p>Metastatic or Relapsed – Collecting Duct/Medullary Subtypes</p>\n </td>\n <td style=\"width: 34%; border-right: 1px solid; vertical-align: top\">\n <h4>REFERENCES:</h4>\n <ol>\n <li><a href=\"http://www.example.org/professionals/physician_gls/PDF/kidney.pdf\">NCCN Guidelines® for Kidney Cancer. V.3.2015.</a></li>\n <li><a href=\"http://www.ncbi.nlm.nih.gov/pubmed?term=%22The+Journal+of+urology%22%5BJour%5D+AND+1698%5Bpage%5D+AND+2007%5Bpdat%5D+AND+Oudard+S%5Bauthor%5D\">Oudard S, et al. <em>J Urol</em>. 2007;177(5):1698-702.</a><sup>\n <a href=\"http://www.example.org/OrderTemplates/PDF/appendix_E.pdf\">a</a></sup>\n </li>\n </ol>\n </td>\n <td style=\"width: 33%; vertical-align: top\">\n <h4>NCCN SUPPORTIVE CARE:</h4>\n <ol>\n <li>\n <i>Emetic Risk:</i>\n <table>\n <tr>\n <td>Day 1</td>\n <td>Moderate</td>\n </tr>\n <tr>\n <td>Day 8</td>\n <td>Low</td>\n </tr>\n </table>\n </li>\n <li>\n <i>Fever Neutropenia Risk:</i><br/>\n Refer to <a href=\"http://www.example.org/professionals/physician_gls/PDF/myeloid_growth.pdf\">NCCN Guidelines for Myeloid Growth Factors. V.2.2014</a>\n </li>\n </ol>\n </td>\n </tr>\n </table>\n <!-- same as the regimen section of the Composition resource only this version is without the style guide notes -->\n <h4>CHEMOTHERAPY REGIMEN</h4>\n <p>\n <i>21-day cycle for 6 cycles</i>\n </p>\n <ul>\n <li>Gemcitabine 1250 mg/m<sup>2</sup> IV over 30 minutes on Days 1 and 8</li>\n <li>CARBOplatin AUC 5 IV over 30 minutes on Day 1</li>\n </ul>\n </div>"
"resourceType" : "PlanDefinition",
"id" : "KDN5",
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n <table style=\"width: 100%;\">\n <tr>\n <td>\n <div style=\"width: 200px; height: 100px; vertical-align: top;\">National Comprehensive Cancer Network</div>\n </td>\n <td>\n <h3>Chemotherapy Order Template</h3>\n <h1>Kidney Cancer</h1>\n <h2>Gemcitabine/CARBOplatin</h2>\n </td>\n <td style=\"text-align: right; vertical-align: top;\">KDN5</td>\n </tr>\n </table>\n <table style=\"width: 100%; border-top: 1px solid; border-bottom: 1px solid;\">\n <tr>\n <td style=\"width: 33%; border-right: 1px solid; vertical-align: top\">\n <h4>INDICATION:</h4>\n <p>Metastatic or Relapsed – Collecting Duct/Medullary Subtypes</p>\n </td>\n <td style=\"width: 34%; border-right: 1px solid; vertical-align: top\">\n <h4>REFERENCES:</h4>\n <ol>\n <li>\n <a href=\"http://www.example.org/professionals/physician_gls/PDF/kidney.pdf\">NCCN Guidelines® for Kidney Cancer. V.3.2015.</a>\n </li>\n <li>\n <a href=\"http://www.ncbi.nlm.nih.gov/pubmed?term=%22The+Journal+of+urology%22%5BJour%5D+AND+1698%5Bpage%5D+AND+2007%5Bpdat%5D+AND+Oudard+S%5Bauthor%5D\">Oudard S, et al. \n <em>J Urol</em>. 2007;177(5):1698-702.\n </a>\n <sup>\n <a href=\"http://www.example.org/OrderTemplates/PDF/appendix_E.pdf\">a</a>\n </sup>\n </li>\n </ol>\n </td>\n <td style=\"width: 33%; vertical-align: top\">\n <h4>NCCN SUPPORTIVE CARE:</h4>\n <ol>\n <li>\n <i>Emetic Risk:</i>\n <table>\n <tr>\n <td>Day 1</td>\n <td>Moderate</td>\n </tr>\n <tr>\n <td>Day 8</td>\n <td>Low</td>\n </tr>\n </table>\n </li>\n <li>\n <i>Fever Neutropenia Risk:</i>\n <br/>\n Refer to \n <a href=\"http://www.example.org/professionals/physician_gls/PDF/myeloid_growth.pdf\">NCCN Guidelines for Myeloid Growth Factors. V.2.2014</a>\n </li>\n </ol>\n </td>\n </tr>\n </table>\n <h4>CHEMOTHERAPY REGIMEN</h4>\n <p>\n <i>21-day cycle for 6 cycles</i>\n </p>\n <ul>\n <li>Gemcitabine 1250 mg/m\n <sup>2</sup> IV over 30 minutes on Days 1 and 8\n </li>\n <li>CARBOplatin AUC 5 IV over 30 minutes on Day 1</li>\n </ul>\n </div>"
},
"contained": [
{
"resourceType": "ActivityDefinition",
"id": "1111",
"status": "draft",
"productCodeableConcept": {
"coding": [
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"code": "12574",
"display": "gemcitabine"
}
],
"text": "gemcitabine"
"contained" : [{
"resourceType" : "ActivityDefinition",
"id" : "1111",
"status" : "draft",
"productCodeableConcept" : {
"coding" : [{
"system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
"code" : "12574",
"display" : "gemcitabine"
}],
"text" : "gemcitabine"
},
"dosage" : [{
"text" : "1250 mg/m² IV over 30 minutes",
"timing" : {
"repeat" : {
"duration" : 30,
"durationUnit" : "min"
}
},
"dosage": [
{
"text": "1250 mg/m² IV over 30 minutes",
"timing": {
"repeat": {
"duration": 30,
"durationUnit": "min"
}
},
"route": {
"text": "IV"
},
"doseAndRate": [
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/dose-rate-type",
"code": "ordered",
"display": "Ordered"
}
]
},
"doseQuantity": {
"value": 1250,
"unit": "mg/m²"
}
}
]
"route" : {
"text" : "IV"
},
"doseAndRate" : [{
"type" : {
"coding" : [{
"system" : "http://terminology.hl7.org/CodeSystem/dose-rate-type",
"code" : "ordered",
"display" : "Ordered"
}]
},
"doseQuantity" : {
"value" : 1250,
"unit" : "mg/m²"
}
]
}]
}]
},
{
"resourceType" : "ActivityDefinition",
"id" : "2222",
"status" : "draft",
"productCodeableConcept" : {
"coding" : [{
"system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
"code" : "40048",
"display" : "Carboplatin"
}],
"text" : "CARBOplatin"
},
{
"resourceType": "ActivityDefinition",
"id": "2222",
"status": "draft",
"productCodeableConcept": {
"coding": [
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"code": "40048",
"display": "Carboplatin"
}
],
"text": "CARBOplatin"
"dosage" : [{
"text" : "AUC 5 IV over 30 minutes",
"timing" : {
"repeat" : {
"duration" : 30,
"durationUnit" : "min"
}
},
"dosage": [
{
"text": "AUC 5 IV over 30 minutes",
"timing": {
"repeat": {
"duration": 30,
"durationUnit": "min"
}
},
"route": {
"text": "IV"
},
"doseAndRate": [
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/dose-rate-type",
"code": "ordered",
"display": "Ordered"
}
]
},
"doseQuantity": {
"extension": [
{
"url": "http://example.org/fhir/AUC-dose",
"valueInteger": 5
}
]
}
}
]
"route" : {
"text" : "IV"
},
"doseAndRate" : [{
"type" : {
"coding" : [{
"system" : "http://terminology.hl7.org/CodeSystem/dose-rate-type",
"code" : "ordered",
"display" : "Ordered"
}]
},
"doseQuantity" : {
"extension" : [{
"url" : "http://example.org/fhir/AUC-dose",
"valueInteger" : 5
}]
}
]
}
],
"identifier": [
{
"system": "http://example.org/ordertemplates",
"value": "KDN5"
}]
}]
}],
"extension" : [{
"url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg",
"valueCode" : "cds"
}],
"identifier" : [{
"system" : "http://example.org/ordertemplates",
"value" : "KDN5"
},
{
"system" : "urn:ietf:rfc:3986",
"value" : "urn:oid:2.16.840.1.113883.4.642.11.21"
}],
"version" : "1",
"name" : "GemcitabineCARBOplatin",
"title" : "Gemcitabine/CARBOplatin",
"type" : {
"text" : "Chemotherapy Order Template"
},
"status" : "draft",
"experimental" : true,
"publisher" : "HL7 International / Clinical Decision Support",
"contact" : [{
"telecom" : [{
"system" : "url",
"value" : "http://www.hl7.org/Special/committees/dss"
}]
}],
"description" : "Gemcitabine/CARBOplatin",
"useContext" : [{
"code" : {
"system" : "http://example.org/fhir/CodeSystem/indications",
"code" : "treamentSetting-or-diseaseStatus"
},
"valueCodeableConcept" : {
"text" : "Metastatic"
}
],
"version": "1",
"title": "Gemcitabine/CARBOplatin",
"type": {
"text": "Chemotherapy Order Template"
},
"status": "draft",
"experimental": true,
"publisher": "National Comprehensive Cancer Network, Inc.",
"useContext": [
{
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/usagecontext-group",
"valueString": "A"
}
],
"code": {
"system": "http://example.org/fhir/CodeSystem/indications",
"code": "treamentSetting-or-diseaseStatus"
},
"valueCodeableConcept": {
"text": "Metastatic"
}
{
"code" : {
"system" : "http://example.org/fhir/CodeSystem/indications",
"code" : "disease-or-histology"
},
{
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/usagecontext-group",
"valueString": "A"
}
],
"code": {
"system": "http://example.org/fhir/CodeSystem/indications",
"code": "disease-or-histology"
},
"valueCodeableConcept": {
"text": "Collecting Duct/Medullary Subtypes"
}
"valueCodeableConcept" : {
"text" : "Collecting Duct/Medullary Subtypes"
}
},
{
"code" : {
"system" : "http://terminology.hl7.org/CodeSystem/usage-context-type",
"code" : "focus"
},
{
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/usagecontext-group",
"valueString": "A"
}
],
"code": {
"system": "http://terminology.hl7.org/CodeSystem/usage-context-type",
"code": "focus"
},
"valueCodeableConcept": {
"text": "Kidney Cancer"
}
"valueCodeableConcept" : {
"text" : "Kidney Cancer"
}
},
{
"code" : {
"system" : "http://example.org/fhir/CodeSystem/indications",
"code" : "treatmentSetting-or-diseaseStatus"
},
{
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/usagecontext-group",
"valueString": "B"
}
],
"code": {
"system": "http://example.org/fhir/CodeSystem/indications",
"code": "treatmentSetting-or-diseaseStatus"
},
"valueCodeableConcept": {
"text": "Relapsed"
}
"valueCodeableConcept" : {
"text" : "Relapsed"
}
},
{
"code" : {
"system" : "http://example.org/fhir/CodeSystem/indications",
"code" : "disease-or-histology"
},
{
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/usagecontext-group",
"valueString": "B"
}
],
"code": {
"system": "http://example.org/fhir/CodeSystem/indications",
"code": "disease-or-histology"
},
"valueCodeableConcept": {
"text": "Collecting Duct/Medullary Subtypes"
}
"valueCodeableConcept" : {
"text" : "Collecting Duct/Medullary Subtypes"
}
},
{
"code" : {
"system" : "http://terminology.hl7.org/CodeSystem/usage-context-type",
"code" : "focus"
},
{
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/usagecontext-group",
"valueString": "B"
}
],
"code": {
"system": "http://terminology.hl7.org/CodeSystem/usage-context-type",
"code": "focus"
},
"valueCodeableConcept": {
"text": "Kidney Cancer – Collecting Duct/Medullary Subtypes - Metastatic"
}
"valueCodeableConcept" : {
"text" : "Kidney Cancer – Collecting Duct/Medullary Subtypes - Metastatic"
}
],
"copyright": "All rights reserved.",
"approvalDate": "2016-07-27",
"lastReviewDate": "2016-07-27",
"author": [
{
"name": "Lee Surprenant"
}],
"copyright" : "All rights reserved.",
"approvalDate" : "2016-07-27",
"lastReviewDate" : "2016-07-27",
"author" : [{
"name" : "Lee Surprenant"
}],
"relatedArtifact" : [{
"type" : "derived-from",
"display" : "NCCN Guidelines for Kidney Cancer. V.2.2016",
"document" : {
"url" : "http://www.example.org/professionals/physician_gls/PDF/kidney.pdf"
}
],
"relatedArtifact": [
{
"type": "derived-from",
"display": "NCCN Guidelines for Kidney Cancer. V.2.2016",
"url": "http://www.example.org/professionals/physician_gls/PDF/kidney.pdf"
},
{
"type" : "citation",
"_type" : {
"extension" : [{
"url" : "http://example.org/fhir/regimenReferenceType",
"valueCode" : "a"
}]
},
{
"type": "citation",
"_type": {
"extension": [
{
"url": "http://example.org/fhir/regimenReferenceType",
"valueCode": "a"
}
]
},
"citation": "Oudard S, et al. J Urol. 2007;177(5):1698-702",
"url": "http://www.ncbi.nlm.nih.gov/pubmed/17437788"
"citation" : "Oudard S, et al. J Urol. 2007;177(5):1698-702",
"document" : {
"url" : "http://www.ncbi.nlm.nih.gov/pubmed/17437788"
}
],
"action": [
{
"selectionBehavior": "exactly-one",
"action": [
{
"selectionBehavior": "all",
"action": [
{
"groupingBehavior": "sentence-group",
"selectionBehavior": "exactly-one",
"action": [
{
"id": "cycle-definition-1",
"textEquivalent": "21-day cycle for 6 cycles",
"timingTiming": {
"repeat": {
"count": 6,
"duration": 21,
"durationUnit": "d"
}
},
"action": [
{
"id": "action-1",
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/timing-daysOfCycle",
"extension": [
{
"url": "day",
"valueInteger": 1
},
{
"url": "day",
"valueInteger": 8
}
]
}
],
"textEquivalent": "Gemcitabine 1250 mg/m² IV over 30 minutes on days 1 and 8",
"definitionCanonical": "#1111"
},
{
"id": "action-2",
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/timing-daysOfCycle",
"extension": [
{
"url": "day",
"valueInteger": 1
}
]
}
],
"textEquivalent": "CARBOplatin AUC 5 IV over 30 minutes on Day 1",
"relatedAction": [
{
"actionId": "action-1",
"relationship": "concurrent-with-start"
}
],
"definitionCanonical": "#2222"
}
]
}
]
}],
"action" : [{
"selectionBehavior" : "exactly-one",
"action" : [{
"selectionBehavior" : "all",
"action" : [{
"groupingBehavior" : "sentence-group",
"selectionBehavior" : "exactly-one",
"action" : [{
"id" : "cycle-definition-1",
"textEquivalent" : "21-day cycle for 6 cycles",
"timingTiming" : {
"repeat" : {
"count" : 6,
"duration" : 21,
"durationUnit" : "d"
}
]
}
]
}
]
},
"action" : [{
"id" : "action-1",
"extension" : [{
"url" : "http://hl7.org/fhir/StructureDefinition/timing-daysOfCycle",
"extension" : [{
"url" : "day",
"valueInteger" : 1
},
{
"url" : "day",
"valueInteger" : 8
}]
}],
"textEquivalent" : "Gemcitabine 1250 mg/m² IV over 30 minutes on days 1 and 8",
"definitionCanonical" : "#1111"
},
{
"id" : "action-2",
"extension" : [{
"url" : "http://hl7.org/fhir/StructureDefinition/timing-daysOfCycle",
"extension" : [{
"url" : "day",
"valueInteger" : 1
}]
}],
"textEquivalent" : "CARBOplatin AUC 5 IV over 30 minutes on Day 1",
"relatedAction" : [{
"targetId" : "action-1",
"relationship" : "concurrent-with-start"
}],
"definitionCanonical" : "#2222"
}]
}]
}]
}]
}]
}
Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.
FHIR
®©
HL7.org
2011+.
FHIR
Release
4
(Technical
Correction
#1)
(v4.0.1)
R6
hl7.fhir.core#6.0.0-ballot3
generated
on
Fri,
Sat,
Nov
1,
2019
09:36+1100.
QA
Page
8,
2025
00:00+0000.
Links:
Search
|
Version
History
|
Table
of
Contents
|
Credits
Glossary
|
QA
|
Compare
to
R3
R4
|
Compare
to
R5
|
Compare
to
Last
Ballot
|
|
Propose
a
change